Core Viewpoint - Nocera Health (09969) has experienced a significant stock increase of over 11%, currently trading at HKD 13.15, with a transaction volume of HKD 155 million [1] Financial Performance - The company has issued a positive earnings forecast, expecting revenue of approximately RMB 2.37 billion in 2025, representing a year-on-year growth of about 134% [1] - Nocera Health anticipates its first net profit of around RMB 630 million in 2025, marking a turnaround from previous losses [1] Growth Drivers - The anticipated growth in revenue is primarily attributed to the rapid increase in drug sales and business development (BD) income [1] - The company plans to continue its globalization efforts, aiming to complete two BD transactions throughout 2025 [1] Product and Market Strategy - According to Ping An Securities, the core product, Oubatinib, is steadily gaining market traction, with comprehensive strategies in hematological malignancies, autoimmune diseases, and solid tumors [1] - The company is actively pursuing external collaborations, with plans to finalize two licensing agreements in 2025, which will contribute to upfront payments and future milestone revenue recognition [1] Revenue Forecast - Revenue projections for 2025-2027 have been revised upwards to RMB 2.371 billion, RMB 2.575 billion, and RMB 2.732 billion, respectively [1] - The expected revenue growth rates for 2025, 2026, and 2027 are 134.9%, 8.6%, and 6.1% respectively [1]